Clinical Trials Logo

Clinical Trial Summary

Cryptococcal meningitis or "Crypto" is a life threatening fungal infection around the brain that requires hospitalization for treatment for 14 days and then continued therapy. Crypto causes 15-20% of HIV/AIDS-related deaths worldwide. However, this infection can be detected before one develops symptoms and becomes ill. People can be screened for infection by a blood test to detect "cryptococcal antigen," (called CrAg), which is part of the fungus, in blood. The World Health Organization and over 22 countries worldwide recommend CrAg screening of all persons with advanced AIDS entering or re-entering into HIV care.

However, it is not known how best to treat people with cryptococcal antigen in their blood, who don't otherwise yet have symptoms of infection around their brain. If no treatment is given, almost all people will develop infection of the brain and/or die. International guidelines suggest using both HIV medicines and an anti-fungal medicine, called fluconazole, to treat this early infection. However, despite this treatment approximately 1 in 4 people may get sick and/or die.

Researchers have recently discovered another medicine that may work against the Cryptococcus fungus. This medicine is called Sertraline, and it is actually a medicine that has been used for more than 25 years to treat depression (sadness). Sertraline is one of the most commonly used medicines worldwide.

The purpose of this research clinical trial is to determine if standard fluconazole antifungal therapy plus a high dose of Sertraline, will be better than standard fluconazole therapy alone for treating early disseminated cryptococcal infection in persons who are asymptomatic and do not yet have infection of the brain (i.e. meningitis).

This study seeks to test if Sertraline will improve survival through 6-months. Prior studies have shown that >90% of those who survive 6-months will survive >5 years.

Clinical Trial Description

This is a double-blind, randomized placebo-controlled clinical trial testing sertraline as an antifungal medicine in combination with fluconazole for treatment of HIV-infected persons with AIDS and asymptomatic cryptococcal antigenemia (CrAg+). ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03002012
Study type Interventional
Source University of Minnesota
Status Terminated
Phase Phase 3
Start date November 15, 2017
Completion date March 13, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT02454569 - Vicente Ferrer HIV Cohort Study
Completed NCT03993093 - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Completed NCT00001701 - Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection N/A
Completed NCT01535469 - Operational Research for Cryptococcal Antigen Screening Phase 4
Completed NCT00784368 - A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Phase 3
Recruiting NCT04554875 - Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
Recruiting NCT04033718 - Inpatient Package to Reduce HIV and AIDS-related Death in Zambia N/A
Enrolling by invitation NCT02503449 - Clinical Trial of Pulmonary Cryptococcosis in China N/A
Active, not recruiting NCT03267407 - Vietnam Cryptococcal Retention in Care Study - Version 2.1 N/A
Completed NCT00647907 - A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Phase 4